Afib drug market expected to decline as brand therapies go generic

jarun011/iStock via Getty Images

Although many branded drugs have a large portion of the atrial fibrillation (Afib) market, the loss of patent exclusivity and the introduction of generics will cause this market to decline between now and 2032.

drugs such as PfizerNew York Stock Exchange: PFE) AndOTCPK: Paysafe

AfibBrandDeclinedrugexpectedgenericmarkettherapies
Comments (0)
Add Comment